catalpol has been researched along with triptolide in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Dong, S; Feng, Z; Liu, T; Liu, Z; Zhou, C; Zhou, L; Zhou, X | 1 |
| Feng, Z; Fu, L; Geng, S; Li, M; Lu, W; Lu, Y; Zhou, L; Zhou, X | 1 |
| Feng, Z; Fu, L; Li, C; Shen, M; Xie, T; Xu, G; Yu, Z; Zhang, L; Zhou, J; Zhou, L; Zhou, X; Zhu, H | 1 |
3 other study(ies) available for catalpol and triptolide
| Article | Year |
|---|---|
Catalpol and panax notoginseng saponins synergistically alleviate triptolide-induced hepatotoxicity through Nrf2/ARE pathway.
Topics: Antioxidant Response Elements; Cell Line; Chemical and Drug Induced Liver Injury; Diterpenes; Drug Synergism; Epoxy Compounds; Humans; Iridoid Glucosides; NF-E2-Related Factor 2; Panax notoginseng; Phenanthrenes; Saponins; Signal Transduction | 2019 |
Catalpol coordinately regulates phase I and II detoxification enzymes of Triptolide through CAR and NRF2 pathways to reduce Triptolide-induced hepatotoxicity.
Topics: Animals; Chemical and Drug Induced Liver Injury; Constitutive Androstane Receptor; Cytochrome P-450 Enzyme System; Disease Models, Animal; Diterpenes; Epoxy Compounds; Female; Glucuronosyltransferase; Hep G2 Cells; Hepatocytes; Humans; Iridoid Glucosides; Liver; Metabolic Detoxication, Phase I; Metabolic Detoxication, Phase II; NF-E2-Related Factor 2; Phenanthrenes; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Signal Transduction | 2020 |
Protection of catalpol against triptolide-induced hepatotoxicity by inhibiting excessive autophagy via the PERK-ATF4-CHOP pathway.
Topics: Activating Transcription Factor 4; Autophagy; Chemical and Drug Induced Liver Injury; eIF-2 Kinase; Humans | 2022 |